Search Patents
-
Publication number: 20110230549Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.Type: ApplicationFiled: April 26, 2011Publication date: September 22, 2011Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Philip Robson
-
Patent number: 9675579Abstract: The present invention relates to the use of tetrahydrocannabivarin (THCV) in the treatment of nausea and vomiting. Preferably the THCV is isolated and/or purified from cannabis plant extracts. Preferably the nausea and/or vomiting is caused by the effects of a medication such as a chemotherapeutic agent.Type: GrantFiled: April 14, 2014Date of Patent: June 13, 2017Assignee: GW Pharma LimitedInventors: Erin Rock, Linda Parker, Marnie Duncan, Colin Stott
-
Patent number: 8771760Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.Type: GrantFiled: April 26, 2011Date of Patent: July 8, 2014Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Philip Robson
-
Publication number: 20100035978Abstract: The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10.Type: ApplicationFiled: October 31, 2006Publication date: February 11, 2010Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Philip Robson
-
Patent number: 7968594Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.Type: GrantFiled: April 27, 2005Date of Patent: June 28, 2011Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Philip Robson
-
Patent number: 9421187Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.Type: GrantFiled: November 21, 2012Date of Patent: August 23, 2016Assignee: GW Pharma LimitedInventors: Angelo Antonio Izzo, Francesca Borrelli, Stephen Wright
-
Publication number: 20140287067Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).Type: ApplicationFiled: November 14, 2013Publication date: September 25, 2014Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., LimitedInventors: Guillermo Velasco Diez, Manuel Guzman Pastor, Mar Lorente, Sofia Torres, Fatima Rodriguez
-
Publication number: 20140378539Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.Type: ApplicationFiled: May 18, 2012Publication date: December 25, 2014Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
-
Publication number: 20140107192Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.Type: ApplicationFiled: May 18, 2012Publication date: April 17, 2014Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
-
Publication number: 20130245109Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: ApplicationFiled: June 1, 2012Publication date: September 19, 2013Applicant: GW Pharma LimitedInventor: Brian Anthony Whittle
-
Publication number: 20130109747Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.Type: ApplicationFiled: June 1, 2012Publication date: May 2, 2013Applicant: GW Pharma LimitedInventor: Brian Anthony Whittle
-
Publication number: 20100016418Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.Type: ApplicationFiled: June 21, 2007Publication date: January 21, 2010Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Barbara Costa
-
Publication number: 20120004251Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.Type: ApplicationFiled: March 30, 2011Publication date: January 5, 2012Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
-
Publication number: 20080119544Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type n diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.Type: ApplicationFiled: November 15, 2005Publication date: May 22, 2008Applicant: GW PHARMA LIMITEDInventors: Geoffrey William Guy, Roger Pertwee
-
Publication number: 20120245224Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.Type: ApplicationFiled: June 7, 2012Publication date: September 27, 2012Applicant: GW Pharma LimitedInventors: Geoffrey Guy, Barbara Costa
-
Patent number: 9669002Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.Type: GrantFiled: September 11, 2015Date of Patent: June 6, 2017Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Roger Pertwee
-
Patent number: 9949937Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: April 24, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956185Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956184Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
-
Patent number: 9956183Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).Type: GrantFiled: March 3, 2017Date of Patent: May 1, 2018Assignee: GW Pharma LimitedInventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky